Follow The Filings

VSTM Verastem Inc.

Health Care, filed as VERASTEM INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 3 managers in 2026 Q2

  • 3 Owners
  • Max 0.6%
  • $9.9M
  • 1 new 2 add

In 2026 Q2 James Silverman opened a position in Verastem, and Torray Investment Partners and Palo Alto Investors added.

Who owns this now

Largest portfolio weights among holders, up to 0.6% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman New 0.62%
  2. Torray Investment Partners Add 0.25%
  3. Palo Alto Investors Add 0.16%

Who owns VSTM

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.62% New 0.62% 1,800,000 $6.9M History
Torray Investment Partners 0.25%, was 0.24% Add +59.7% 477,455 $1.8M History
Palo Alto Investors 0.16% Add +25.8% 309,685 $1.2M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by VSTM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VSTM insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $1.1M sold by 6 insiders under 10b5-1 plans
  1. Dan Paterson CEO
    Planned sale
    $353K 44,121 shares at $8.00 6.3% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  2. Daniel Calkins CFO
    Planned sale
    $21K 2,566 shares at $8.00 2% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  3. Daniel Calkins CFO
    Planned sale
    $424 55 shares at $7.70 <0.1% of stake
    Traded Sep 21 Filed Sep 23
    ↗
  4. Dan Paterson CEO
    Planned sale
    $7,565 1,302 shares at $5.81 0.2% of stake
    Traded Aug 3 Filed Aug 5
    ↗
  5. Dan Paterson CEO
    Planned sale
    $87K 20,871 shares at $4.18 3.4% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  6. Daniel Calkins CFO
    Planned sale
    $17K 4,089 shares at $4.18 3.4% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  7. Dan Paterson CEO
    Planned sale
    $4,691 806 shares at $5.82 0.1% of stake
    Traded May 4 Filed May 6
    ↗
  8. Dan Paterson CEO
    Planned sale
    $6,489 970 shares at $6.69 0.2% of stake
    Traded Feb 4 Filed Feb 5
    ↗
  9. Dan Paterson CEO
    Planned sale
    $74K 10,321 shares at $7.16 2.5% of stake
    Traded Jan 12 Filed Jan 14
    ↗
  10. Daniel Calkins CFO
    Planned sale
    $36K 5,039 shares at $7.16 4.6% of stake
    Traded Jan 12 Filed Jan 14
    ↗
  11. Daniel Calkins CFO
    Planned sale
    $629 80 shares at $7.86 0.1% of stake
    Traded Dec 24, 2025 Filed Dec 29, 2025
    ↗
  12. Brian M Stuglik Director
    Planned sale
    $5,411 592 shares at $9.14 0.6% of stake
    Traded Dec 16, 2025 Filed Dec 18, 2025
    ↗
  13. Dan Paterson CEO
    Planned sale
    $3,592 393 shares at $9.14 0.1% of stake
    Traded Dec 16, 2025 Filed Dec 18, 2025
    ↗
  14. Robert E. Gagnon Director
    Planned sale
    $2,587 283 shares at $9.14 0.7% of stake
    Traded Dec 16, 2025 Filed Dec 18, 2025
    ↗
  15. Dan Paterson CEO
    Planned sale
    $40K 4,000 shares at $10.04 1% of stake
    Traded Dec 10–11 Filed Dec 12, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 13 stock grants and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 2.02,5.02,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,2.03,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $10M —
Net income -$87.37M -$130.64M -$209.47M
Net margin * — -1306.4% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $143.68M $94.96M $223.41M
Total non-current assets * $6.04M $6.58M $23.03M
Total assets $149.72M $101.54M $246.44M
Total current liabilities $26.38M $30.97M $72.27M
Total non-current liabilities * $44.8M $99.46M $116.98M
Total equity $57.37M -$28.89M $57.2M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$86.46M -$104.77M -$137.51M
Cash from investing -$44.45M $59.97M -$9.62M
Cash from financing $134.19M $54.78M $263.3M
Net change in cash $3.29M $9.98M $116.17M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.